NervGen Pharma Corp. (NGEN)vsBeiGene, Ltd. (ONC)
NGEN
NervGen Pharma Corp.
$3.63
-3.20%
HEALTHCARE · Cap: $311.58M
ONC
BeiGene, Ltd.
$295.27
+1.54%
HEALTHCARE · Cap: $33.18B
Smart Verdict
WallStSmart Research — data-driven comparison
ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
NGEN
Avoid17
out of 100
Grade: F
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for NGEN.
Margin of Safety
+79.8%
Fair Value
$1738.29
Current Price
$295.27
$1443.02 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : NGEN
NGEN has a balanced fundamental profile.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : NGEN
The primary concerns for NGEN are Revenue Growth, EPS Growth, Market Cap.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 120.5x leaves little room for execution misses.
Key Dynamics to Monitor
NGEN profiles as a value stock while ONC is a hypergrowth play — different risk/reward profiles.
NGEN carries more volatility with a beta of 0.99 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 17/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
NervGen Pharma Corp.
HEALTHCARE · BIOTECHNOLOGY · USA
Nanogen Inc (NGEN) is a cutting-edge biotechnology company dedicated to advancing molecular diagnostic technologies aimed at improving patient outcomes through innovative genomic analysis solutions. The firm specializes in the development and commercialization of products tailored to complex disease targets, utilizing its proprietary platforms to deliver precise and timely diagnostics. With a robust focus on research and development, Nanogen is poised to expand its portfolio and drive growth in the dynamic diagnostic market, aligning with the industry's shift toward personalized medicine and the increasing demand for sophisticated diagnostic tools.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?